WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :
Dr. Muhammad Baqir MR Fakhrildin
Download Article: Click Here

Search

Track Your Article

Abstract

DIAGNOSTIC AND PREDICTIVE DNA MARKERS IN SUDANESE PATIENTS WITH COLORECTAL CANCER “THE IMPACT OF ERCC1, XPD, KRAS AND APC GENE’S POLYMORPHISM ON SUDANESE PATIENTS WITH COLORECTAL CANCER

Fariada Babikir A. Badri*, Elsheikh A. Elobeid and Adila Salih El-Obeid

ABSTRACT

Aim: The current study is to examine whether polymorphisms in
(ERCC1, ERCC2 (XPD), KRAS, APC) genes have any impact on the
risk of colorectal cancer in Sudanese population, also identify their role
in clinical outcome and toxicity profile on patients treated with 5-
Flurouracil (FU)/Oxaliplatin for colorectal cancer. Method: In total,
50 patients with CRC were recruited, 47 of them received (FOLFOX)
treatment as a first- line chemotherapy. Polymorphism in one oncogene
(KRAS), one tumor suppressor gene (APC) and two DNA-repairing
genes (ERCC1, ERCC2) were assessed in these patients using
polymerase chain reaction (PCR), and PCR-restriction fragment length
polymorphism (PCR-RFLP) techniques. The correlation between these
polymorphisms and risk of CRC also with the incidence of oxaliplatin
toxicity were evaluated. Result: ERCC1 118, XPD 751 T,C alleles
respectively and mutated KRAS genotypes associated with risk for developing colorectal
cancer in Sudanese population with percentages (14%,12%,24%) respectively. Besides no
significant association between APC I1307K variant and risk of CRC in Sudanese
population, but results show a high prevalence of this variant in Sudanese population
(patients and healthy individuals) which may predict an ethnic difference. Also our results showed that patients with either ERCC1 118 T/T , XPD 751 C/C ,APC wild genotypes show lower incidence of oxaliplatin toxicity. A stastically siginicant association between the oxaliplatin toxicity and XPD 751 (p= 0.02) and APC I1307K (p=0.01) were identified. Conclusion: Overall, our findings suggest that mutated KRAS, ERCC1 C>T, and XPD A>C have a good impact on CRC risk in Sudanese patients, also mutated KRAS, ERCC1 C>T, XPD A>C and APC I1307K may predict oxaliplatin toxicity in patients treated with oxaliplatin based chemotherapy.

Keywords: ERCC1, ERCC2 (XPD), KRAS, APC, Oxaliplatin.


[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More